Groupama Asset Managment Reduces Stake in Eli Lilly and Company

The investment firm sold 15,395 shares of the pharmaceutical giant in the third quarter.

Mar. 19, 2026 at 9:37am

Got story updates? Submit your updates here. ›

Groupama Asset Managment, an investment firm, reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 14.7% during the third quarter, according to a recent SEC filing. The firm now owns 89,223 shares of the company's stock, down from 104,618 shares previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs and therapies. Changes in institutional ownership of the stock can provide insights into market sentiment and potential future performance.

The details

In its 13F filing, Groupama Asset Managment reported selling 15,395 shares of Eli Lilly during the third quarter. The firm's total holdings in the company are now valued at $68,077,000. Eli Lilly's stock has seen significant volatility in recent months as the company navigates patent expirations, new drug launches, and the competitive pharmaceutical landscape.

  • Groupama Asset Managment filed its 13F report for the third quarter of 2026.

The players

Groupama Asset Managment

A global investment management firm that oversees over $500 billion in assets.

Eli Lilly and Company

A multinational pharmaceutical company headquartered in Indianapolis, Indiana that develops and markets drugs and therapies worldwide.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Groupama's Eli Lilly holdings reflects broader market uncertainty around the pharmaceutical industry, but Eli Lilly remains a major player with a robust pipeline of new drugs. Investors will continue to watch the company's performance and strategic moves closely.